Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

来那度胺 Carfilzomib公司 多发性骨髓瘤 地塞米松 医学 肿瘤科 内科学 药理学
作者
Elizabeth O’Donnell,Clifton C. Mo,Andrew J. Yee,Omar Nadeem,Jacob P. Laubach,Jacalyn Rosenblatt,Nikhil C. Munshi,Shonali Midha,Diana Cirstea,Pavlina Chrysafi,Nora Horick,Paul G. Richardson,Noopur Raje
出处
期刊:The Lancet Haematology [Elsevier]
被引量:3
标识
DOI:10.1016/s2352-3026(24)00070-x
摘要

Summary

Background

Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk.

Methods

This single-arm phase 2 trial was done at three cancer centres (two hospitals and a cancer institute) in Boston (MA, USA). Eligible patients were aged at least 18 years and had transplant-eligible newly diagnosed multiple myeloma and an ECOG performance status of 2 or less. Patients received four 28-day cycles of Isa-KRd, including isatuximab 10 mg/kg intravenously weekly for 8 weeks, then every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m2 intravenously on days 1, 8, and 15 (20 mg/m2 for cycle 1 day 1); lenalidomide 25 mg orally on days 1–21; and dexamethasone 20 mg orally the day of and day after all doses of carfilzomib and isatuximab. Consolidation involved either upfront haematopoietic stem-cell transplantation (HSCT) with two additional cycles or deferred HSCT with four additional cycles of treatment. The primary endpoint was complete response after four cycles of treatment. Analyses were by intention-to-treat. All patients who received one dose of study drug were included in the safety analyses. This study was registered at ClinicalTrials.gov, NCT04430894, and has completed enrolment.

Findings

Between July 31, 2020 and Jan 31, 2022, 50 patients were enrolled. Median age was 59 years (range 40–70), 54% (27 of 50 patients) were male, and 44 (88%) were White. 46% (23 of 50) of patients had high-risk cytogenetics. Median follow-up was 26 months (IQR 20·7–30·1). 32% (16 of 50 patients) achieved a complete response after four cycles. The overall response rate (ORR) was 90% (45 patients) and 78% (39 patients) achieved a very good partial response (VGPR) or better. After completion of consolidation, 58% (29 patients) achieved a complete response; the ORR was 90% (45 patients) and 86% (43 patients) achieved a VGPR or better. The most common grade 3 or 4 side-effects (≥two patients) included neutropenia (13 [26%] of 50 patients), elevated alanine aminotransferase (six [12%] patients), fatigue (three [6%] patients), thrombocytopenia (three [6%] patients), acute kidney injury (two [4%] patients), anaemia (two [4%] patients), and febrile neutropenia (two [4%] patients). Grade 1–2 infusion-related reactions were seen in 20% (ten patients), with none grade 3. Grade 1–2 hypertension was seen in 14% (seven patients) with one grade 3 (one [2%] patient). There were two deaths assessed as unrelated to treatment.

Interpretation

Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.

Funding

Amgen, Sanofi, and Adaptive.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黑球发布了新的文献求助10
1秒前
阳光森林完成签到 ,获得积分10
2秒前
一二完成签到 ,获得积分10
3秒前
酷波er应助科研通管家采纳,获得10
3秒前
薰硝壤应助科研通管家采纳,获得10
4秒前
薰硝壤应助科研通管家采纳,获得10
4秒前
所所应助科研通管家采纳,获得10
4秒前
迅速千愁完成签到 ,获得积分10
7秒前
Talha完成签到,获得积分10
9秒前
guoxingliu完成签到,获得积分10
11秒前
tjpuzhang完成签到 ,获得积分10
14秒前
Wei完成签到 ,获得积分10
21秒前
Bagpipe完成签到 ,获得积分10
30秒前
kytlnj完成签到 ,获得积分0
32秒前
褚洙完成签到,获得积分10
34秒前
34秒前
fourhaits完成签到,获得积分10
35秒前
37秒前
活泼的匕完成签到 ,获得积分10
41秒前
Joy完成签到,获得积分10
43秒前
花痴的骁完成签到 ,获得积分10
45秒前
朱诗源完成签到 ,获得积分10
45秒前
瘦瘦马里奥完成签到,获得积分10
51秒前
LXZ完成签到,获得积分10
54秒前
韧迹完成签到 ,获得积分10
54秒前
超体完成签到 ,获得积分10
57秒前
zhangh65完成签到,获得积分10
57秒前
自由的无色完成签到 ,获得积分10
57秒前
xiaofeng5838完成签到,获得积分10
58秒前
雪白的紫翠完成签到 ,获得积分10
59秒前
白白不焦虑完成签到,获得积分10
1分钟前
艾欧比完成签到 ,获得积分10
1分钟前
丘比特应助Jaja采纳,获得10
1分钟前
研友_VZG7GZ应助吱吱采纳,获得10
1分钟前
聪明小丸子完成签到,获得积分10
1分钟前
kingkingwang2013完成签到,获得积分20
1分钟前
Barbarian完成签到,获得积分10
1分钟前
善学以致用应助黑球采纳,获得10
1分钟前
9239完成签到 ,获得积分10
1分钟前
幼荷完成签到 ,获得积分10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709891
关于积分的说明 7418319
捐赠科研通 2354494
什么是DOI,文献DOI怎么找? 1246122
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921